A research team led by Professor Dean Ho has harnessed the power of artificial...
A research team led by Professor Dean Ho has harnessed the power of artificial intelligence to dramatically accelerate the discovery of drug combination therapies.

Fighting infectious diseases using AI

Researchers have developed an artificial intelligence platform to dramatically increase the efficiency of this development.

As the COVID-19 crisis continues to develop, researchers around the world are attempting to find the most effective treatment to combat the poorly understood virus behind this disease. Traditionally, when dangerous new bacterial and viral infections emerge, the response is to develop a treatment that combines several different drugs.

However, this process is laborious and time-consuming, with drug combinations chosen sub-optimally, and selection of doses is a matter of trial and error. This costly and inefficient way of developing a treatment is problematic when a rapid response is crucial to tackle a global pandemic and resources need to be conserved.

With this in mind, Professor Dean Ho from the National University of Singapore (NUS) led a multidisciplinary team of researchers to come up with a pioneering artificial intelligence (AI) platform known as "IDentif.AI' (Identifying Infectious Disease Combination Therapy with Artificial Intelligence) to dramatically increase the efficiency of this development.

Drawbacks of traditional drug screening

Conventional selection of drugs for treatment involves examining virus or bacteria growth in response to different potential candidates. The drugs are given to the bacteria or viruses at increasing dosages until maximal prevention of their growth is observed. Additional drugs are then added together to amplify the effect. However, these methods become ineffective when several drugs are simultaneously studied as candidates. Also, these approaches often result in positive outcomes for in vitro studies, but are not observed in human studies.

"If 10 or more drugs are examined, it is virtually impossible to study the effects of all the possible drug combinations and dosages needed to identify the best possible combination using traditional methods," explained Prof Ho, Director of The N.1 Institute for Health and Institute for Digital Medicine (WisDM) at NUS.

Furthermore, in traditional screening, if a drug from a pool of candidate therapies is shown to have no apparent effect on the pathogen, this drug will generally no longer be considered. "However, if this drug is systematically combined with more drugs, each at the correct doses, this could very well result in the best possible combination. Unfortunately, this remarkable level of required precision cannot be arbitrarily derived," added Prof Ho, who is also the Head of the NUS Department of Biomedical Engineering.

Using AI to optimise drug therapies

To avoid the drawbacks of traditional drug combination therapy development, Prof Ho and his team, together with collaborators from Shanghai Jiao Tong University harnessed the processing power of AI.

The research team carefully selected 12 drugs which are viable candidates for treating an infection in lung cells caused by the vesicular stomatitis virus (VSV). They then used IDentif.AI to markedly reduce the number of experiments needed to interrogate the full range of combinations and optimal dosages of these 12 drugs. "Using IDentif.AI, we took three days to identify multiple optimal drug regimens out of billions of possible combinations that reduced the VSV infection to 1.5 percent with no apparent adverse impact. This speed and accuracy in discovering new drug combination therapies is completely unprecedented," said Prof Ho.

Importantly, the team saw that when the top-ranked drug combination was optimally dosed, it was seven times more effective compared to sub-optimal doses. This shows the critical importance of ideal drug and dose identification.

Similarly, when a single drug was substituted out from the top-ranked drug combination, and this new combination was administered at sub-optimal doses, the combination was 14 times less effective. "There is a notion in drug discovery that if you discover the right molecule, the work is done. Our results with IDentif.AI prove that it is critically important to think about how the drug is developed into a combination and subsequently administered. How do you combine it with the right drugs? How do you dose this drug properly? Answering these questions can dramatically increase efficacy at the clinical stage of drug development," shared Prof Ho.

In addition to validating IDentif.AI, this study also included insights by a team of experts in operations research and healthcare economics from NUS Business School and KPMG Global Health and Life Sciences Centre of Excellence, as well as global health security and surveillance experts from EpiPointe LLC and MRIGlobal. They concluded that strategies such as IDentif.AI, which can rapidly optimise drug repurposing under austere economic conditions amidst pandemics, could play a key role in improving patient outcomes compared to standard approaches.

Using IDentif.AI against COVID-19 and more

Having proved the effectiveness of IDentif.AI to rapidly provide treatments for infectious diseases, the team is currently setting their sights on COVID-19.

Prof Ho said, "As the development of vaccines and antibody therapies for COVID-19 are ongoing, we will need a rapid therapeutic strategy that addresses the virus which may evolve over time. Our strength is that we can perform one experiment and come out with a list of drug combinations for treatment within days. And in time, if patients do not respond well to the first combinations of drugs, we can derive new combinations within days to re-optimise their care. Our platform is useful to address the possibility that patients will need different drug combinations depending on when treatment was initiated, and if downstream infection with a different strain occurs."

Furthermore, IDentif.AI could be immediately deployed to address any other infectious diseases in the future. Prof Ho concluded, "When an aggressive pathogen hits, a rapid response is needed, and this response may need to evolve quickly as the pathogen evolves. Now, with IDentif.AI, we will be ready."

Subscribe to our newsletter

Related articles

AI, App provide at-home assessment of coronavirus risk

AI, App provide at-home assessment of coronavirus risk

A coronavirus app coupled with machine intelligence will soon enable an individual to get an at-home risk assessment based on how they feel and where they've been in about a minute.

Acute chikungunya infection studied with AI

Acute chikungunya infection studied with AI

Computational tools applied to biology are revolutionizing the study of what happens inside cells during an infection, helping scientists to understand disease mechanisms.

Using AI in the fight against river blindness

Using AI in the fight against river blindness

Researchers want to develop a method in which artificial intelligence automatically evaluates tissue samples from patients under the microscope.

Organtransplantation: Biophotonic therapy kills infections

Organtransplantation: Biophotonic therapy kills infections

Scientists have developed a new technique for the decontamination of organs before transplantation using ultraviolet and red light irradiation.

AI detects the presence of viruses

AI detects the presence of viruses

UCLA researchers have developed a rapid and automated biosensing method based on holography coupled with deep learning.

AI identifies likely wildlife hosts for emerging flaviviruses

AI identifies likely wildlife hosts for emerging flaviviruses

After collecting data and comparing it with every known mammal and bird species on Earth, scientists have identified wildlife species that are the most likely to host flaviviruses such as Zika, West Nile, dengue and yellow fever.

‘Smart’ surfaces promise safer implants

‘Smart’ surfaces promise safer implants

Researchers design “smart” surfaces, creating promise for safer implants and more accurate diagnostic tests.

AI diagnostic can predict COVID-19 without testing

AI diagnostic can predict COVID-19 without testing

Researchers at King’s College London, Massachusetts General Hospital and health science company ZOE have developed an AI diagnostic that can predict whether someone is likely to have COVID-19 based on their symptoms.

A novel swab design to augment COVID-19 testing

A novel swab design to augment COVID-19 testing

Scientists have developed a novel test swab that can be 3D printed using inexpensive, widely available materials and speedily assembled in a range of fabrication settings.

Popular articles